APO 010

Drug Profile

APO 010

Alternative Names: APO010

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Apoxis
  • Developer Onxeo SA
  • Class Antineoplastics; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Apoptosis stimulants; CD95 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 30 Dec 2016 APO 010 licensed to 2X Oncology
  • 30 Dec 2016 Oncology Venture in-licenses Drug Response Prediction (DRP™) technology from Medical Prognosis Institute with three year world-wide exclusivity
  • 08 Aug 2016 Phase-I development is ongoing in Switzerland in Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top